Axicef 500

Axicef 500 mg Tablet (Cefuroxime Axetil) — Clinical Overview

What is Axicef 500 mg?

Axicef 500 mg Tab is a higher-dose formulation of cefuroxime axetil, a second-generation oral cephalosporin antibiotic manufactured by ACI Limited, Bangladesh. The 500 mg dose is prescribed when greater antibiotic exposure is required — typically for more severe or deeply-seated infections, or for infections caused by organisms with higher minimum inhibitory concentrations (MICs) that require a higher drug concentration to be effectively eliminated.

Like the 250 mg strength, Axicef 500 mg is an ester prodrug that is hydrolyzed to active cefuroxime in the gut mucosa. Bioavailability is increased by ~40% when taken with food, making food co-administration mandatory for optimal therapeutic outcomes.

When is the 500 mg Dose Required?

The choice between 250 mg and 500 mg doses of cefuroxime axetil is guided by infection severity, site of infection, and causative pathogen characteristics:

• Acute exacerbations of chronic bronchitis (AECB) in COPD: 500 mg twice daily is recommended to achieve bronchial secretion concentrations sufficient to eradicate H. influenzae and M. catarrhalis, which may have higher MICs in patients with repeated antibiotic exposure.
• Severe sinusitis: When infection extends beyond the antrum or when first-line therapy has failed, 500 mg twice daily provides higher sinus mucosal drug levels.
• Mild community-acquired pneumonia (CAP): 500 mg twice daily provides tissue concentrations needed to treat S. pneumoniae and H. influenzae in the lower respiratory tract.
• Early disseminated Lyme disease: 500 mg twice daily for 20 days is the standard oral regimen for Lyme borreliosis with erythema migrans.
• Skin and soft tissue infections: More extensive cellulitis or infected surgical wounds may require 500 mg twice daily to achieve effective tissue and skin concentrations.

How Does Cefuroxime Axetil Work?

Cefuroxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking peptidoglycan cross-linking and causing bacterial lysis. It is a time-dependent antibiotic — efficacy depends on maintaining free drug concentrations above the MIC for at least 40–50% of the dosing interval. At 500 mg twice daily, higher peak plasma concentrations (Cmax ~7–10 μg/mL) ensure that time above MIC is maintained for a broader range of organisms and strains with higher MICs, providing bactericidal activity against more challenging infections.

Cefuroxime is stable against many plasmid-mediated beta-lactamases from H. influenzae (TEM-1, TEM-2) and M. catarrhalis (BRO-1, BRO-2), which commonly cause respiratory tract infections.

Diabetes and Higher-Dose Antibiotic Therapy

Diabetic patients often require the higher 500 mg dose for several reasons:

• Impaired drug distribution: Microvascular disease in diabetes reduces antibiotic penetration into peripheral tissues (skin, subcutaneous tissue, bone). Higher serum concentrations from 500 mg dosing help compensate for reduced tissue perfusion, particularly in lower limb infections.
• Diabetic foot infections (DFIs): Mild-to-moderate non-limb-threatening DFIs often involve MSSA, streptococci, and occasionally Gram-negative organisms. Cefuroxime axetil 500 mg twice daily is an acceptable oral option per IWGDF guidelines when IV therapy is not required.
• AECB in diabetics with COPD: Diabetics have a higher prevalence of COPD. During acute bronchitis exacerbations, 500 mg twice daily achieves sputum concentrations of ~1–2 μg/mL, above the MIC90 of most H. influenzae and M. catarrhalis strains.
• Stress hyperglycaemia: Severe infections cause pronounced cortisol release, significantly raising blood glucose. Aggressive antibiotic therapy with the 500 mg dose may lead to faster infection resolution and earlier glucose stabilisation.

Dosage and Administration

• AECB / severe sinusitis: 500 mg twice daily × 7–10 days
• Community-acquired pneumonia: 500 mg twice daily × 7–14 days
• Early Lyme disease: 500 mg twice daily × 20 days
• Skin / soft tissue infections (moderate): 500 mg twice daily × 7–14 days

Always take with food to maximise bioavailability. Swallow tablets whole — do not crush or chew. Complete the full prescribed course. Renal dose adjustment: CrCl 10–30 mL/min → consider 250 mg twice daily; CrCl <10 mL/min → 250 mg once daily.

Drug Interactions

• Probenecid: Increases cefuroxime plasma levels by blocking renal tubular secretion
• PPIs / H2-blockers / antacids: Reduce absorption; partially offset by taking with food
• Warfarin: May potentiate anticoagulant effect; monitor INR
• Oral contraceptives: Reduced efficacy due to gut flora changes; use barrier contraception
• Nephrotoxic agents: Monitor renal function when combining with NSAIDs, aminoglycosides

Side Effects

• Common: Diarrhoea, nausea, vomiting, headache, abdominal pain, rash. Higher doses may increase GI side effect frequency.
• Uncommon: Elevated liver enzymes (ALT/AST), eosinophilia, positive Coombs' test
• Rare: Anaphylaxis, Stevens-Johnson syndrome, Clostridioides difficile colitis

Contraindications

• Known hypersensitivity to cefuroxime, cephalosporins, or any excipient
• History of severe immediate penicillin hypersensitivity (anaphylaxis) — ~1–2% cross-reactivity

Frequently Asked Questions (FAQ)